Emily H. Cheng - Publications

Affiliations: 
Biology & Biomedical Sciences (Molecular Cell Biology) Washington University, Saint Louis, St. Louis, MO 
Area:
Cell Biology

34 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Hsieh JJ, Cheng EH. Exploiting the circuit breaker cancer evolution model in human clear cell renal cell carcinoma. Cell Stress. 4: 191-198. PMID 32743344 DOI: 10.15698/cst2020.08.227  0.56
2019 Xu J, Reznik E, Lee HJ, Gundem G, Jonsson P, Sarungbam J, Bialik A, Sanchez-Vega F, Creighton CJ, Hoekstra JG, Zhang L, Sajjakulnukit P, Kremer D, Tolstyka ZP, Casuscelli J, ... ... Cheng EH, et al. Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma. Elife. 8. PMID 30924768 DOI: 10.7554/Elife.38986  0.56
2019 Xu J, Reznik E, Lee H, Gundem G, Jonsson P, Sarungbam J, Bialik A, Sanchez-Vega F, Creighton CJ, Hoekstra J, Zhang L, Sajjakulnukit P, Kremer D, Tolstyka Z, Casuscelli J, ... ... Cheng EH, et al. Author response: Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma Elife. DOI: 10.7554/Elife.38986.025  0.56
2019 Tanaka K, Han S, Ganesan YT, Hsieh JJ, Cheng EH. Abstract 698: Enhancing apoptosis to improve the therapy ofEGFR-mutant lung cancer Cancer Research. 79: 698-698. DOI: 10.1158/1538-7445.Am2019-698  0.56
2018 Dong Y, Eskandari R, Ray C, Granlund KL, Dos Santos-Cunha L, Miloushev VZ, Tee SS, Jeong S, Aras O, Chen YB, Cheng EH, Hsieh JJ, Keshari KR. Hyperpolarized MRI visualizes Warburg effects and predicts treatment response to mTOR inhibitors in patient-derived ccRCC xenograft models. Cancer Research. PMID 30459151 DOI: 10.1158/0008-5472.Can-18-2231  0.56
2018 Hsieh JJ, Le VH, Oyama T, Ricketts CJ, Ho TH, Cheng EH. Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018792549. PMID 30372397 DOI: 10.1200/Jco.2018.79.2549  0.56
2018 Jeng PS, Inoue-Yamauchi A, Hsieh JJ, Cheng EH. BH3-Dependent and Independent Activation of BAX and BAK in Mitochondrial Apoptosis. Current Opinion in Physiology. 3: 71-81. PMID 30334018 DOI: 10.1016/J.Cophys.2018.03.005  0.56
2017 Hsieh JJ, Le V, Cao D, Cheng EH, Creighton CJ. Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision. The Journal of Pathology. PMID 29266437 DOI: 10.1002/Path.5022  0.56
2017 Becerra MF, Reznik E, Redzematovic A, Tennenbaum DM, Kashan M, Ghanaat M, Casuscelli J, Manley B, Jonsson P, DiNatale RG, Blum KA, Durack JC, Solomon SB, Arcila ME, Bourque C, ... ... Cheng EH, et al. Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. European Urology Focus. PMID 29066084 DOI: 10.1016/J.Euf.2017.09.016  0.56
2017 Nargund AM, Osmanbeyoglu HU, Cheng EH, Hsieh JJ. SWI/SNF tumor suppressor gene PBRM1/BAF180 in human clear cell kidney cancer. Molecular & Cellular Oncology. 4: e1342747. PMID 28868352 DOI: 10.1080/23723556.2017.1342747  0.56
2017 Inoue-Yamauchi A, Jeng PS, Kim K, Chen HC, Han S, Ganesan YT, Ishizawa K, Jebiwott S, Dong Y, Pietanza MC, Hellmann MD, Kris MG, Hsieh JJ, Cheng EH. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. Nature Communications. 8: 16078. PMID 28714472 DOI: 10.1038/Ncomms16078  0.56
2017 Casuscelli J, Weinhold N, Gundem G, Wang L, Zabor EC, Drill E, Wang PI, Nanjangud GJ, Redzematovic A, Nargund AM, Manley BJ, Arcila ME, Donin NM, Cheville JC, Thompson RH, ... ... Cheng EH, et al. Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. Jci Insight. 2. PMID 28614790 DOI: 10.1172/Jci.Insight.92688  0.56
2017 Nargund AM, Pham CG, Dong Y, Wang PI, Osmangeyoglu HU, Xie Y, Aras O, Han S, Oyama T, Takeda S, Ray CE, Dong Z, Berge M, Hakimi AA, Monette S, ... ... Cheng EH, et al. The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma. Cell Reports. 18: 2893-2906. PMID 28329682 DOI: 10.1016/J.Celrep.2017.02.074  0.56
2017 Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, ... ... Cheng EH, et al. Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology. 18: 46. PMID 28249590 DOI: 10.1186/S13059-017-1180-8  0.56
2016 Dong Y, Manley BJ, Becerra MF, Redzematovic A, Casuscelli J, Tennenbaum DM, Reznik E, Han S, Benfante N, Chen YB, Arcila ME, Aras O, Voss MH, Feldman DR, Motzer RJ, ... ... Cheng EH, et al. Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. European Urology Focus. PMID 28753786 DOI: 10.1016/J.Euf.2016.08.005  0.56
2016 Hsieh JJ, Cheng EH. The panoramic view of clear cell renal cell carcinoma metabolism: values of integrated global cancer metabolomics. Translational Andrology and Urology. 5: 984-986. PMID 28078239 DOI: 10.21037/Tau.2016.11.03  0.56
2016 Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, ... ... Cheng EH, et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology. 17: 231. PMID 27855702 DOI: 10.1186/S13059-016-1092-Z  0.56
2016 Garner TP, Reyna DE, Priyadarshi A, Chen HC, Li S, Wu Y, Ganesan YT, Malashkevich VN, Cheng EH, Gavathiotis E. An Autoinhibited Dimeric Form of BAX Regulates the BAX Activation Pathway. Molecular Cell. 64: 431. PMID 27768876 DOI: 10.1016/J.Molcel.2016.10.005  0.36
2016 Hsieh JJ, Cheng EH. A braided cancer river connects tumor heterogeneity and precision medicine. Clinical and Translational Medicine. 5: 42. PMID 27766604 DOI: 10.1186/S40169-016-0123-4  0.56
2016 Hsieh JJ, Chen D, Wang PI, Marker M, Redzematovic A, Chen YB, Selcuklu SD, Weinhold N, Bouvier N, Huberman KH, Bhanot U, Chevinsky MS, Patel P, Pinciroli P, Won HH, ... ... Cheng EH, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. European Urology. PMID 27751729 DOI: 10.1016/J.Eururo.2016.10.007  0.56
2016 Chen YB, Xu J, Skanderup AJ, Dong Y, Brannon AR, Wang L, Won HH, Wang PI, Nanjangud GJ, Jungbluth AA, Li W, Ojeda V, Hakimi AA, Voss MH, Schultz N, ... ... Cheng EH, et al. Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nature Communications. 7: 13131. PMID 27713405 DOI: 10.1038/Ncomms13131  0.56
2016 Hsieh JJ, Manley B, Khan N, Gao J, Carlo MI, Cheng EH. Overcome Tumor Heterogeneity-Imposed Therapeutic Barriers through Convergent Genomic Biomarker Discovery: A Braided Cancer River Model of Kidney Cancer. Seminars in Cell & Developmental Biology. PMID 27615548 DOI: 10.1016/J.Semcdb.2016.09.002  0.56
2016 Mandal T, Shin S, Aluvila S, Chen HC, Grieve C, Choe JY, Cheng EH, Hustedt EJ, Oh KJ. Assembly of Bak homodimers into higher order homooligomers in the mitochondrial apoptotic pore. Scientific Reports. 6: 30763. PMID 27488021 DOI: 10.1038/Srep30763  0.36
2016 Xu J, Pham CG, Albanese SK, Dong Y, Oyama T, Lee CH, Rodrik-Outmezguine V, Yao Z, Han S, Chen D, Parton DL, Chodera JD, Rosen N, Cheng EH, Hsieh JJ. Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. The Journal of Clinical Investigation. PMID 27482884 DOI: 10.1172/Jci86120  0.56
2016 Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, Luna A, Aksoy BA, Liu EM, Shen R, Lee W, Chen Y, Stirdivant SM, Russo P, Chen YB, Tickoo SK, ... ... Cheng EH, et al. An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell. 29: 104-116. PMID 26766592 DOI: 10.1016/J.Ccell.2015.12.004  0.56
2016 Inoue-Yamauchi A, Jeng P, Kim K, Chen H, Han S, Ganesan YT, Dong Y, Jebiwott S, Hsieh JJ, Cheng EH. Abstract 3555: Targeting the BCL-2 family in small cell lung caner Cancer Research. 76: 3555-3555. DOI: 10.1158/1538-7445.Am2016-3555  0.56
2015 Niizuma H, Cheng EH, Hsieh JJ. Taspase 1: A protease with many biological surprises. Molecular & Cellular Oncology. 2: e999513. PMID 27308523 DOI: 10.1080/23723556.2014.999513  0.56
2015 Chen HC, Kanai M, Inoue-Yamauchi A, Tu HC, Huang Y, Ren D, Kim H, Takeda S, Reyna DE, Chan PM, Ganesan YT, Liao CP, Gavathiotis E, Hsieh JJ, Cheng EH. An interconnected hierarchical model of cell death regulation by the BCL-2 family. Nature Cell Biology. PMID 26344567 DOI: 10.1038/Ncb3236  0.36
2014 Sankin A, Hakimi AA, Mikkilineni N, Ostrovnaya I, Silk MT, Liang Y, Mano R, Chevinsky M, Motzer RJ, Solomon SB, Cheng EH, Durack JC, Coleman JA, Russo P, Hsieh JJ. The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. Cancer Medicine. 3: 1485-92. PMID 25124064 DOI: 10.1002/Cam4.293  0.56
2014 Voss MH, Hakimi AA, Pham CG, Brannon AR, Chen YB, Cunha LF, Akin O, Liu H, Takeda S, Scott SN, Socci ND, Viale A, Schultz N, Sander C, Reuter VE, ... ... Cheng EH, et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1955-64. PMID 24622468 DOI: 10.1158/1078-0432.CCR-13-2345  0.56
2013 Voss MH, Hakimi AA, Pham CG, Brannon AR, Chen Y, Cunha LF, Akin O, Liu H, Takeda S, Scott SN, Socci ND, Viale A, Schultz N, Sander C, Reuter VE, ... ... Cheng EH, et al. Abstract 3515: Pathway convergent evolution underscores treatment response to MTOR inhibitors in kidney cancers. Cancer Research. 73: 3515-3515. DOI: 10.1158/1538-7445.Am2013-3515  0.56
2010 Liu H, Takeda S, Kumar R, Westergard TD, Brown EJ, Pandita TK, Cheng EH, Hsieh JJ. Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature. 467: 343-6. PMID 20818375 DOI: 10.1038/Nature09350  0.56
2009 Liu H, Cheng EH, Hsieh JJ. MLL fusions: pathways to leukemia. Cancer Biology & Therapy. 8: 1204-11. PMID 19729989  0.56
2003 Hsieh JJ, Cheng EH, Korsmeyer SJ. Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression. Cell. 115: 293-303. PMID 14636557 DOI: 10.1016/S0092-8674(03)00816-X  0.56
Show low-probability matches.